Global InformationTrubion information
 | This article relies excessively on references to primary sources. (May 2009) |
 | |
| Company type | Public company |
|---|---|
Traded as | Nasdaq: TRBN |
| Industry | Biopharmaceutical |
| Founded | 1999 |
| Fate | acquired by Emergent BioSolutions (2010) |
| Headquarters | Seattle, WA |
| Products | Protein-based therapeutics |
| Website | www.trubion.com |
Trubion was a publicly held biopharmaceutical company that was focused on creating a pipeline of protein-based therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. Trubion was acquired by Emergent BioSolutions on October 28, 2010.[1] Trubion was established in 1999 in the State of Washington as an early stage development company, and was later reincorporated in October 2002 in the State of Delaware.
In December 2005, Trubion entered into a collaborative agreement with Wyeth[2] for the development and worldwide commercialization of CD20-directed therapeutics. The agreement also included the development and worldwide commercialization of certain other product candidates directed to targets other than CD20. The research portion of Trubion's contract with Wyeth extended through December 22, 2009.
- ^ "Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals | Reuters". www.reuters.com. Archived from the original on 5 December 2014. Retrieved 13 January 2022.
- ^ "Wyeth.com | CBD - Trubion Alliance". Archived from the original on 2008-08-28. Retrieved 2008-07-30.